Flurbiprofen
As of the edition of 20 October 2026, Flurbiprofen is a small molecule: marketed, first approved in 1977 (CH); acts on PTGS1 and PTGS2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2011
- Kind
- Small molecule
- Brand name
- Ocufen
- First approved
- 13 September 1977 (CH)
- Approvals on record
- 11 in 5 regions
- Holder of the most recent approval
- Reckitt Benckiser; 7 holders in all
- Registered trials
- 42, 0 stopped early
- Disease areas
- Infections; Lungs and airways; Mouth and teeth; Bones, joints and muscles; Ear, nose and throat; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product4 company-target rows are on route B because of Flurbiprofen.
See the 4 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 9 | 4 | 3 | 0 |
| Phase 1 | 20 | 20 | 0 | 0 |
| Phase 2 | 4 | 4 | 0 | 0 |
| Phase 3 | 3 | 3 | 0 | 0 |
| Phase 4 | 6 | 5 | 0 | 0 |
| All trials | 42 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Applicant | 1986 to now |
| Pfizer | Later holder and Lead sponsor of trials | 1988 to now |
| Reckitt Benckiser | Applicant and Lead sponsor of trials | 2009 to now |